These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 24900409)
1. Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease. Huang X; Zhou W; Liu X; Li H; Sun G; Mandal M; Vicarel M; Zhu X; Bennett C; McCraken T; Pissarnitski D; Zhao Z; Cole D; Gallo G; Zhu Z; Palani A; Aslanian R; Clader J; Czarniecki M; Greenlee W; Burnett D; Cohen-Williams M; Hyde L; Song L; Zhang L; Chu I; Buevich A ACS Med Chem Lett; 2012 Nov; 3(11):931-5. PubMed ID: 24900409 [TBL] [Abstract][Full Text] [Related]
2. γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not. Lessard CB; Rodriguez E; Ladd TB; Minter LM; Osborne BA; Miele L; Golde TE; Ran Y Alzheimers Res Ther; 2020 May; 12(1):61. PubMed ID: 32430033 [TBL] [Abstract][Full Text] [Related]
3. Development and mechanism of γ-secretase modulators for Alzheimer's disease. Crump CJ; Johnson DS; Li YM Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767 [TBL] [Abstract][Full Text] [Related]
4. Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators. Jung JI; Ran Y; Cruz PE; Rosario AM; Ladd TB; Kukar TL; Koo EH; Felsenstein KM; Golde TE Biochemistry; 2014 Apr; 53(12):1947-57. PubMed ID: 24620716 [TBL] [Abstract][Full Text] [Related]
5. The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease. Li H; Qin J; Dhondi P; Zhou W; Vicarel M; Bara T; Cole D; Josien H; Pissarnitski D; Zhu Z; Palani A; Aslanian R; Clader J; Czarniecki M; Greenlee W; Cohen-Williams M; Hyde L; Song L; Zhang L; Chu I; Huang X Bioorg Med Chem Lett; 2013 Jan; 23(2):466-71. PubMed ID: 23253441 [TBL] [Abstract][Full Text] [Related]
6. γ-Secretase Modulators: Can We Combine Potency with Safety? Gijsen HJ; Mercken M Int J Alzheimers Dis; 2012; 2012():295207. PubMed ID: 23365783 [TBL] [Abstract][Full Text] [Related]
7. Presenilin is the molecular target of acidic γ-secretase modulators in living cells. Jumpertz T; Rennhack A; Ness J; Baches S; Pietrzik CU; Bulic B; Weggen S PLoS One; 2012; 7(1):e30484. PubMed ID: 22238696 [TBL] [Abstract][Full Text] [Related]
8. γ-Secretase modulator in Alzheimer's disease: shifting the end. Xia W; Wong ST; Hanlon E; Morin P J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916 [TBL] [Abstract][Full Text] [Related]
10. Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator. Bursavich MG; Harrison BA; Acharya R; Costa DE; Freeman EA; Hrdlicka LA; Jin H; Kapadnis S; Moffit JS; Murphy D; Nolan SJ; Patzke H; Tang C; Van Voorhies HE; Wen M; Koenig G; Blain JF; Burnett DA J Med Chem; 2021 Oct; 64(19):14426-14447. PubMed ID: 34550687 [TBL] [Abstract][Full Text] [Related]
11. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227 [TBL] [Abstract][Full Text] [Related]
12. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478 [TBL] [Abstract][Full Text] [Related]
13. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects. Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974 [TBL] [Abstract][Full Text] [Related]
14. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246 [TBL] [Abstract][Full Text] [Related]
15. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Bulic B; Ness J; Hahn S; Rennhack A; Jumpertz T; Weggen S Curr Neuropharmacol; 2011 Dec; 9(4):598-622. PubMed ID: 22798753 [TBL] [Abstract][Full Text] [Related]
16. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo. Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401 [TBL] [Abstract][Full Text] [Related]
17. γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP). Lessard CB; Cottrell BA; Maruyama H; Suresh S; Golde TE; Koo EH PLoS One; 2015; 10(12):e0144758. PubMed ID: 26678856 [TBL] [Abstract][Full Text] [Related]